SUPPLEMENTARY INFORMATION


Shimpei Iikuni,† Masahiro Ono,*,† Keiichi Tanimura,† Hiroyuki Watanabe,† Masashi Yoshimura,† Hideo Saji†

†Department of Patho-Functional Bioanalysis, Graduate School of Pharmaceutical Sciences, Kyoto University, 46-29 Yoshida Shimoadachi-cho, Sakyoku, Kyoto 606-8501, Japan.

*To whom correspondence should be addressed: Phone: +81-75-753-4608, Fax: +81-75-753-4568, e-mail: ono@pharm.kyoto-u.ac.jp.
Supplementary Figure S1. Typical HPLC profiles of Re-BAT-C3-PQ-1 (A), Re-BAT-C3-PQ-2 (B), and Re-BAT-C3-PQ-3 (C). The analyses are performed on a Cosmosil C\textsubscript{18} column (5C\textsubscript{18}-AR-II, 4.6 × 150 mm) with a solvent of H\textsubscript{2}O/MeCN [11:9 (0 min) to 1:3 (30 min)] as the mobile phase at a flow rate of 1 mL/min.
Supplementary Figure S2. Chemical structure and $^1$H NMR spectra for compound 9 (Re-BAT-C3-PQ-1).
Supplementary Figure S3. Chemical structure and $^1$H NMR spectra for compound 10 (Re-BAT-C3-PQ-2).
Supplementary Figure S4. Chemical structure and $^1$H NMR spectra for compound 13 (Re-BAT-C3-PQ-3).